top of page

ABOUT MRN DIAGNOSTICS

Front sign

WHO WE ARE

MRN Diagnostics provides a comprehensive toolbox of products and services to the diagnostics, biotechnology, and pharmaceutical industries for the research, development, and commercialization of RUO and In vitro diagnostic tests.  We provide scientific expertise, critical biological materials, GMP manufacturing, analytical service testing and a secure biorepository to support all phases of diagnostic development. Some of this includes:

  • Prospective sample collections for cancer, infectious, cardiac, hepatitis and pulmonary diseases.

  • Archive of 250,000 remnant delinked clinical specimens from global collections

  • Analytical Services Division for high complexity CLIA testing, antigen, antibody and molecular testing

  • ISO13485:2016 Certified manufacturing facilities 

  • FDA Registered Manufacturer

  • Raw bulk biomaterials (serum, plasma, WB)  or processed into stabilized control matricies and finished products

  • Large inventory of validation and seroconversion panels for development

MEET THE EXECUTIVES

GREGORY R. CHIKLIS, PHD.

Chief Executive Officer    

Chief Scientific Officer   

Dr. Chiklis has developed and commercialized thousands of diagnostic research products over his career., including In-vitro kit controls, calibrators, and multiple analytical services for assay validation. These are all designed to support diagnostic development, validation, manufacturing, commercialization, and quality control.  Many of these products have been used to support test kit regulatory submissions and to quality control millions of test results annually.  

Dr. Chiklis graduated from the University of Massachusetts, Amherst in 1986, with a B.S. in Biochemistry, and later from the University of Massachusetts Lowell with a Doctorate in Chemistry in 1992.  He began his career at a start-up, Hemagen Diagnostics, where he developed in-vitro autoimmune and infectious disease assays.  Next, he moved to BioClinical Partners, which eventually became ZeptoMetrix Corporation. There, as Vice President of Research and Development and eventually CEO, he developed and commercialized many more products including his patented NATtrol, noninfectious nucleic acid testing controls. Dr. Chiklis will use MRN's extensive biospecimen archive, prospective collection capabilities, research, and manufacturing facilities to continue to develop state-of-the-art diagnostics.

ROBERT O. MCKIE

Chief Financial Officer    

Chief Operating Officer   

Mr. McKie began his career as a Sales Representative for North American Biologicals in 1986. Continuing his healthcare focus in 1990 he became a Senior Sales Representative with Dianon Systems, Inc. He then moved on to Boston BioMedica, Inc. where from 1992 to 1994, he grew his responsibilities to become Director of Sales. In 1994, Mr. McKie co-founded BioClinical Partners, Inc. and served as Chief Operating Officer until 1999, when the business was acquired by IMPATH Inc.  He was Vice President of Operations for the IMPATH Predictive Oncology™ division and was actively involved in the development and daily management of the company's GeneBank™ initiative and the IMPATH Clinical Trials Network™ (ICTN). Following his work with IMPATH, Mr. McKie provided consulting services on behalf of hospitals and life science companies.  He successfully developed clinical services worldwide, providing protocol-directed and IEC-approved clinical studies that continue to deliver thousands of biospecimens in oncology and infectious diseases annually. Mr. McKie also holds a BS degree in Business from Nova University. At Medical Research Networx, Mr. McKie provides strategic direction for the company with a vision to become the largest and most respected supplier of biospecimens and ancillary products and services to the diagnostics industry.

COMPANY HISTORY

1994
2001
2018
1999
1996
2020

Mr. McKie founded Bioclinical Partners to provide a source of high quality biospecimens with accurate annotation, and a clear chain of custody.

Bioclinical Partners was acquired by IMPATH.

PRESENT

Mr. Morin joined Bioclinical Partners and later formed Bay State Biologicals to continue making high-quality biospecimens available to industry researchers.

Mr. McKie and Mr. Morin formed Medical Research Networx to provide a broad array of services and products to enable research and development of laboratory testing in the life science industry.

Dr. Gregory Chiklis joined the company as CEO/CSO and built a state of the art biorepository and a diagnostic research and manufacturing facility in Franklin, MA where the company now resides.

The COVID-19 Pandemic began, and MRN Diagnostics became one of the first points-of-care for COVID-19 testing, collecting, and researching.

Today, MRN Diagnostics offers multiple products and services for Research, Development, Validation, Manufacturing and commercialization of diagnostic assays.

Dr. Gregory R. Chiklis joined, building a manufacturing facility to manufacture and commercialize hundreds of diagnostic cancer products.

2013
Male Scientist Working

JOIN OUR TEAM

- Phlebotomists

- Laboratory Technicians

- Manufacturing/Assembly Technicians

- Summer Internships

- Office Assistants

- Data Entry

-Quality Control/Quality Assurance

-Materials Management

Keep up with us on LinkedIn and Indeed to stay updated on our open positions and opportunities.

  • indeedicon
  • LinkedIn

STAY UPDATED ON MRNDx NEWS

info@mrndx.com

English (508) 384-0033

Portuguese / Spanish (508) 803-9020

  • alt.text.label.Instagram
  • alt.text.label.LinkedIn
  • alt.text.label.Facebook
  • TikTok

©2024 by MRN Diagnostics. Proudly created with Wix.com

bottom of page